Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 16Carcinoma, Non-Small-Cell Lung 10Ovarian Neoplasms 6Endometrial Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Melanoma 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Stomach Neoplasms 2Rectal Neoplasms 2Osteosarcoma 2Neoplasm Metastasis 2Multiple Myeloma 2Lung Neoplasms 2Colonic Neoplasms 2Rhabdomyosarcoma 1Recurrence 1Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1Neuroblastoma 1Neoplasms by Site 1Hodgkin Disease 1Hepatoblastoma 1Glioblastoma 1Gastrointestinal Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Fallopian Tube Neoplasms 1Ependymoma 1Digestive System Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Renal Cell 1

Interventions

Paclitaxel 47Carboplatin 38liposomal doxorubicin 25Bevacizumab 23Gemcitabine 18Topotecan 15pembrolizumab 14mirvetuximab soravtansine 11rucaparib 8niraparib 7Cisplatin 71-dodecylpyridoxal 7trebananib 6Drug Therapy 6130-nm albumin-bound paclitaxel 6Nivolumab 5Cyclophosphamide 5cemiplimab 4sarilumab 3relacorilant 3pazopanib 3oregovomab 3olaparib 3Doxorubicin 3Docetaxel 3Albumin-Bound Paclitaxel 3tocilizumab 2seribantumab 2phenoxodiol 2pegfilgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Fallopian Tube Neoplasms × dostarlimab × Clear all
NCT05126342 2025-04-06

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

AGO Research GmbH

Phase 2 Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡